Briefing
Early detection of molecular relapse with ctDNA tracking and treatment with palbociclib plus fulvestrant in ER-positive HER2-negative breast cancer
Phase 2 trial of ctDNA surveillance and, in the treatment phase, palbociclib plus fulvestrant versus standard endocrine therapy. Registry primary outcomes include the incidence of a positive ctDNA result and relapse-free survival. ClinicalTrials.gov lists the study as recruiting.
- Design: Phase 2 · Recruiting